Evolus

Evolus reported Q2 2026 revenue of $84.1m (+21% y/y), beating analysts' estimates and raising the lower end of its full-year revenue guidance to $330m. Adjusted EBITDA was positive at $4.7m for the third consecutive quarter, although EPS of -$0.12 was more negative than expected. Management emphasized portfolio diversification through Evolysse and Profhilo and additional product launches; the stock rose about 5.7% in after-hours trading. » More on de.investing.com

Evolus has reached an exclusive license and distribution agreement with Swiss pharmaceutical company IBSA for the skin injection Profhilo in the US. Evolus will assume the development activities required for US approval and will market the product after approval; the agreement includes no upfront payments and is based on a transfer-pricing model. The company expects no impact from the agreement on its 2026 guidance or on the revenue and profitability targets for 2028. Profhilo, a superficially acting hyaluronic acid formulation to improve skin quality, has already been used in millions of treatments worldwide since 2015 and complements Evolus' existing portfolio such as Jeuveau and Evolysse. » More on de.investing.com

At Evolus' annual general meeting, Brady Stewart and Vikram Malik were reelected as Class II directors for three years. Shareholders confirmed Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026, and voted in a non-binding advisory vote to approve the compensation of the named executive officers. Additionally, the company reported mixed Q1 results (EPS missed, revenue slightly above expectations) and plans the European launch of the Estyme dermal filler line. » More on de.investing.com

Evolus will introduce the Estyme collection of four injectable hyaluronic acid gels in Europe on May 16, including the globally first commercially available Estyme Sculpt for mid‑face volume restoration. The products are CE‑certified and use Symatese’s Cold‑X technology; FDA approval for Estyme Sculpt is expected later this year. Evolus reported revenue of $301.79 million for the twelve months to Q1 2026 (≈+10%) but remains unprofitable with a negative EPS of -$0.67. » More on de.investing.com

Evolus presented comprehensive clinical data for its two-pronged approach with Jeuveau and the new Evolysse filler portfolio based on Cold-X™ technology. U.S. approval-relevant studies show that Evolysse Form and Smooth were not only non-inferior but statistically superior to Restylane-L at six months; Evolysse Sculpt achieved non-inferiority and high responder rates for volume augmentation. Jeuveau delivered solid Phase III results versus Botox and data on a higher‑dose formulation with longer duration; safety profiles remained favorable. On the financial side, Evolus reported Q1 revenue of $73.1 million, reaffirmed full-year guidance and is targeting continued double-digit revenue growth and positive adjusted EBITDA. » More on de.investing.com